Business Context and Reporting Period
This Form 8-K was filed by Stellar Biotechnologies, Inc. (not Edesa Biotech, Inc.) on September 02, 2015. The registrant is incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, CA. The report details a corporate action effective as of the filing date.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data provided relates to capital structure adjustments:
- Pre-Split Outstanding Shares: 79,847,550
- Post-Split Outstanding Shares: Approximately 7,984,755
- Reverse Split Ratio: 1-for-10
Material Changes
The Company effected a 1-for-10 reverse stock split of its common shares. This action consolidated every ten issued and outstanding shares into one newly-issued share. Fractional shares less than one-half were cancelled, while fractional shares of at least one-half were rounded up to one whole share. There was no change in the par value per share.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The document strictly reports the execution of the reverse split and references a press release (Exhibit 99.1) for further confirmation.
Investor Verification Checklist
- Verify the updated share count of approximately 7,984,755 in subsequent filings.
- Confirm the treatment of fractional shares for specific shareholder accounts.
- Review the attached press release (Exhibit 99.1) for any additional context regarding the rationale for the split.
- Note the discrepancy between the requested company name (Edesa Biotech) and the actual registrant (Stellar Biotechnologies).